AbbVie Wary Of IRA Potential Impact On Struggling Imbruvica

 
• By Joseph Haas

While AbbVie tries to estimate which of its products might fall into CMS price negotiations, it is seeing lower-than-expected sales erosion for Humira and continued growth for Skyrizi and Rinvoq.

AbbVie Building
AbbVie's projections of Humira sales erosion are holding up well • Source: Shutterstock (Valeriya Zankovych/Shutterstock)

More from Earnings

More from Business